4 results
We want to demonstrate or exclude through this study that the administration of a dilute anesthetic solution, using local tumescent anesthesia technique, will lead to a significant decrease in per-and postoperative pain in patients undergoing…
The aim of this study is to assess the pharmacodynamic effects of different P2Y12 inhibiting therapy (clopdiogrel vs ticagrelor) in patients at high risk for HPR identified according to the ABCD-GENE score in PCI treated patients also requiring OAC…
The primary objective is to compare a 12-month antithrombotic regimen of edoxaban in combination with clopidogrel or another P2Y12 antagonist against a regimen of a vitamin K antagonist (VKA) in combination with clopidogrel or another P2Y12…
The primary efficacy endpoint is to assess ischemic risk of genotype-guided clopidogrel monotherapy during the first 6 months following successful PCI in NSTE-ACS patients.The primary safety endpoint is to assess bleeding risk of genotype-guided…